Efalizumab
Title: Efalizumab
CAS Registry Number: 214745-43-4
CAS Name: Anti-(human CD11a (antigen)) immunoglobulin G1 (human-mouse monoclonal hu1124 g1-chain) disulfide with human-mouse monoclonal hu1124 light chain, dimer
Additional Names: hu1124
Trademarks: Raptiva (Genentech); Xanelim (Genentech)
Literature References: Humanized monoclonal IgG1 antibody directed against the CD11a subunit of lymphocyte function-associated antigen-1 (LFA-1). Inhibits lymphocyte activation, migration and adhesion to endothelial cells. Prepn: P. M. Jardieu, L. G. Presta, WO 9823761; eidem, US 6037454 (1998, 2000 both to Genentech); W. A. Werther et al., J. Immunol. 157, 4986 (1996). Clinical pharmacokinetics: R. J. Bauer et al., J. Pharmacokinet. Biopharm. 27, 397 (1999). Clinical study in psoriasis: M. Lebwohl et al., N. Engl. J. Med. 349, 2004 (2003). Review of pharmacology and therapeutic potential: R. L. Dedrick et al., Transplant Immunol. 9, 181-186 (2002); J. C. Cather et al., Expert Opin. Biol. Ther. 3, 361-370 (2003); of use in chronic psoriasis: J. C. Cather, A. Menter, Expert Opin. Biol. Ther. 5, 393-403 (2005).
Therap-Cat: Antipsoriatic; immunosuppressant.
Keywords: Antipsoriatic.

Others monographs:
ShiononePropyl EtherSuxibuzoneNoformicin
Stearyl AlcoholCamazepamVersenol®Enduracidin
Chlorinated LimeCalcium PhenoxideCalotropinLenthionine
SafroleEthyl CyanoacrylateNornicotineChondrocurine
©2016 DrugLead US FDA&EMEA